Skeletal Radiology

, Volume 41, Issue 3, pp 347–352 | Cite as

Imaging of recurrent intramuscular granulomatous masses induced by depot injection of leuprorelin

  • Emily N. Vinson
  • Andresa Braga-Baiak
  • Leslie G. Dodd
  • Salutario Martinez
Case Report


Leuprorelin is a luteinizing hormone-releasing hormone (LH-RH) agonist that is used as an agent of androgen deprivation in some patients with prostate cancer. When administered in depot form, local granulomatous reactions may occur at the injection site, which may mimic masses and which are associated with treatment failure. We present a patient who, over a period of 5 years, developed multiple intramuscular gluteal masses while receiving leuprorelin therapy via intramuscular depot injections; biopsy of one of the masses showed the specific histologic features of leuprorelin granuloma. To our knowledge, this entity has not been described in the radiology literature. Awareness of this entity is necessary to suggest the correct diagnosis in patients with a history of leuprorelin depot injections.


Prostate cancer Leuprorelin (INN) Leuprolide acetate (USAN) Intramuscular granuloma Sterile abscess GnRH agonist LH-RH agonist MRI PET 


  1. 1.
    Quon H, Loblaw DA. Androgen deprivation therapy for prostate cancer—review of indications in 2010. Curr Oncol. 2010;17:s38–44.PubMedGoogle Scholar
  2. 2.
    Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging. 2009;4:259–67.PubMedGoogle Scholar
  3. 3.
    Marks LS. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology 2003; 62 (Suppl 6A): 36–42.Google Scholar
  4. 4.
    Ouchi T, Koyama T, Miyata N, Sugiura M. Granuloma caused by subcutaneous injection of leuprorelin acetate product: case report and histopathological findings. J Dermatol. 2006;33:719–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Neely EK, Hintz RL, Parker B, et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr. 1992;121:634–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Tonini G, Marinoni S, Forleo V, Rustico M. Local reactions to luteinizing hormone releasing hormone analog therapy [letter]. J Pediatr. 1995;126:159–60.PubMedGoogle Scholar
  7. 7.
    Daskivich TJ, Oh WK. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms? Urology 2006; 67: 1084.e15–1084.e17.Google Scholar
  8. 8.
    de Brito VN, Latronico AC, Arnhold IJP, et al. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. Arch Dis Child. 1999;80:231–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Curry 3rd EA. Sweeney CJ. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. J Urol. 2002;168:193.PubMedCrossRefGoogle Scholar
  10. 10.
    Carel JC, Lahlou N, Guazzarotti L, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol. 1995;132:699–704.PubMedCrossRefGoogle Scholar
  11. 11.
    Yasukawa K, Sawamura D, Sugawara H, Kato N. Leuprorelin acetate granulomas: case reports and review of the literature. Br J Dermatol. 2005;152:1045–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Whitaker IS, Fazel MZ, Joshi HB, Moseley RP, Turner WH. Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injection sites. BJU Int. 2002;90:350.PubMedCrossRefGoogle Scholar
  13. 13.
    Manasco PK, Pescovitz OH, Blizzard RM. Local reactions to depot leuprolide therapy for central precocious puberty [letter]. J Pediatr. 1993;123:334–5.PubMedGoogle Scholar
  14. 14.
    Sakamoto R, Higashi Y, Mera K, Kanekura T, Kanzaki T. Granulomas induced by subcutaneous injection of leuprorelin acetate. J Dermatol. 2006;33:43–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Watanabe T, Yamada N, Yoshida Y, Yamamoto O. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate. J Cutan Pathol. 2009;36:1299–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Dangle P, Palit V, Sundaram SK, Weston P. Noninfective cutaneous granuloma with leuprorelin acetate—reality or myth? Urology. 2007;69:e5–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Saxby M. Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injections sites. BJU Int. 2003;91:125.PubMedCrossRefGoogle Scholar
  18. 18.
    Tachibana M, Yamano Z, Kusuda Y, Hara S, Shimogaki H, Hamami G. [Cutaneous epithelioid granulomas caused by subcutaneous infusion of leuprorelin acetate: a case report.]. Hinyokika Kiyo. 2004;50:199–202.PubMedGoogle Scholar
  19. 19.
    Oida T, Shichiri Y, Takao N, Kanno T, Kanamaru H. [Surgical management of inflammatory granuloma which developed following subcutaneous injection of leuprorelin acetate: a case report.]. Hinyokika Kiyo. 2005;51:487–9.PubMedGoogle Scholar
  20. 20.
    Neely EK, Wilson DM, Hintz RL. Local reactions to depot leuprolide therapy for central precocious puberty [reply to letter]. J Pediatr. 1993;123:334–5.Google Scholar

Copyright information

© ISS 2011

Authors and Affiliations

  • Emily N. Vinson
    • 1
  • Andresa Braga-Baiak
    • 2
  • Leslie G. Dodd
    • 3
  • Salutario Martinez
    • 1
  1. 1.Division of Musculoskeletal Radiology, Department of RadiologyDuke University Medical CenterDurhamUSA
  2. 2.Sugisawa Medical CenterDepartment of RadiologyCuritibaBrazil
  3. 3.Department of PathologyDuke University Medical CenterDurhamUSA
  4. 4.DUMCDurhamUSA

Personalised recommendations